Navigation Links
ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
Date:3/29/2011

ifficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including the therapeutic indication and use, safety, efficacy, tolerability and potential of our C1 esterase inhibitor and our focus, goals, strategy, research and development programs, and ability to develop pharmaceutical products, commercialize pharmaceutical products, and execute on our plans, including clinical development activities with C1 esterase inhibitor related to the treatment of acute antibody-mediated rejection. This is the first study of our C1 esterase inhibitor in the treatment of acute antibody-mediated rejection. There can be no assurance that that our phase 2 clinical program with C1 esterase inhibitor will yield positive results or support further development of C1 esterase inhibitor for treatment of acute antibody-mediated rejection. The FDA or EMA may view the data regarding utilization of C1 esterase inhibitor as treatment of acute antibody-mediated rejection as ins
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
2. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
3. ViroPharma Announces Securities Repurchase Program
4. ViroPharma to Participate in Two March Healthcare Conferences
5. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
6. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
7. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
8. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
9. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
10. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
11. ViroPharma To Participate in Two September Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... NEW YORK, April 27, 2011 ... biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments ... year,s Oncology Nursing Society (ONS) Congress at the Boston Convention ... booth (#652) will be displayed in the Exhibition Hall ...
... Medical Industries, Inc. (OTC: PDMI.PK) announced its success at ... which was held at the Houston Convention Center in ... practice optometrists from many of the most highly regarded ... the annual meeting.  The meeting provided opportunities for participating ...
Cached Medicine Technology:Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 2Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 3Paradigm is Successful at Annual Vision Source Meeting in Houston, Texas 2
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers ... off on its Mother of the Bride Dresses ... the bride dresses from Balfleet.com feature gorgeous looks and ... takes pride in providing high quality dresses to its ... discounts on our mother of the bride dresses, and ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 Sweetdressy.com ... market, has introduced its newest selection of cheap prom ... are very popular in the world and clients can ... , Meanwhile, these prom dresses feature cool cuts and ... $200 now, targeting the middle-end market. Discount shipping costs ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 ... corporation dedicated to developing educational events, tools and ... Rouxbe Cooking School , the world’s leading ... the prescription every human being needs: Culinary Rx. ... plant-based cooking course, Culinary Rx, scheduled for debut ...
(Date:12/19/2014)... Eufaula, Oklahoma, located just 9 miles ... state’s largest lake with more than 600 miles of ... a little more than 3,000 residents, hosted its annual ... 6th of December. , Featuring Santa, Christmas lights and ... on Main Street. Narconon Arrowhead’s parade float participated ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... ... a common technology infrastructure for Policy, Compliance, Risk, SOX, Internal Audits and IT ... ... -- MetricStream, Inc. (“MetricStream”), the market leader in the enterprise-wide Governance, Risk ...
... (NYSE Alternext: ULU), a specialty pharmaceutical company ... and oral care products, today announced it has entered into ... at a price per share of $0.14 pursuant to a ... of approximately $1.5 million. , Investors will also receive warrants ...
... Mass., Nov. 12 Cequent Pharmaceuticals, a pioneer in ... to prevent and treat human disease, has announced that ... application with the U.S. Food and Drug Administration (FDA). ... candidate, targets beta-catenin, a key oncogene implicated in the ...
... Nov. 12 Mary Elizabeth Derig, of Seattle, Washington, ... Edition for her outstanding contributions and achievements in the ... ) , ABOUT MARY ELIZABETH ... an extensive career as a Registered Nurse including work ...
... (NYSE: ABT ) announced today a definitive agreement to ... antibody to Nerve Growth Factor (NGF), expanding the company,s pain ... a novel biologic in Phase I clinical trial development that ... released at sites of tissue damage and inflammation, and plays ...
... ... Mary Alexander will present during Class Action/Mass Torts session discussing tainted food products , ... San Francisco, CA (PRWEB) November 12, ... product law firms in the nation, will take the podium during the 48th Annual Consumer ...
Cached Medicine News:Health News:Amedisys Selects MetricStream for Integrated Enterprise-wide GRC 2Health News:ULURU Inc. to Raise $1.5 Million in Registered Direct Offering 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 3Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 4Health News:Mary Elizabeth Derig Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain 2Health News:California Consumer Attorney Mary Alexander to Present at 48th Annual COAC Convention 2
... microdermabrasion systems offer many features that add ... you time and money. Because our MegaPeel ... to use and maintain, you spend your ... microdermabrasion equipment. MegaPeel microdermabrasion systems are available ...
... the Clareon to practices that require an ... and efficacy. The versatility of the Clareon ... range of treatments that would typically require ... to worry about obsolescence because the Clareon ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
... Many experts say the ... eliminating,vibratory or lateral movement of ... the mechanism of,the ARC-H II ... of the tip is,restricted to ...
Medicine Products: